HPMA-PLGA Based Nanoparticles for Effective In Vitro Delivery of Rifampicin

Overview

Journal Pharm Res

Specialties Pharmacology
Pharmacy

Date 2018 Dec 5

PMID 30511238

Citations 8

Authors

Sarita Rani

Avinash Gothwal

Pawan K Pandey

Devendra S Chauhan

Praveen K Pachouri

Umesh D Gupta

Umesh Gupta

Affiliations

Soon will be listed here.

Abstract

Purpose: Tuberculosis (TB) chemotherapy witnesses some major challenges such as poor water-solubility and bioavailability of drugs that frequently delay the treatment. In the present study, an attempt to enhance the aqueous solubility of rifampicin (RMP) was made via co-polymeric nanoparticles approach. HPMA (N-2-hydroxypropylmethacrylamide)-PLGA based polymeric nanoparticulate system were prepared and evaluated against Mycobacterium tuberculosis (MTB) for sustained release and bioavailability of RMP to achieve better delivery.

Methodology: HPMA-PLGA nanoparticles (HP-NPs) were prepared by modified nanoprecipitation technique, RMP was loaded in the prepared NPs. Characterization for particle size, zeta potential, and drug-loading capacity was performed. Release was studied using membrane dialysis method.

Results: The average particles size, zeta potential, polydispersity index of RMP loaded HPMA-PLGA-NPs (HPR-NPs) were 260.3 ± 2.21 nm, -6.63 ± 1.28 mV, and 0.303 ± 0.22, respectively. TEM images showed spherical shaped NPs with uniform distribution without any cluster formation. Entrapment efficiency and drug loading efficiency of HPR-NPs were found to be 76.25 ± 1.28%, and 26.19 ± 2.24%, respectively. Kinetic models of drug release including Higuchi and Korsmeyer-peppas demonstrated sustained release pattern. Interaction studies with human RBCs confirmed that RMP loaded HP-NPs are less toxic in this model than pure RMP with (p < 0.05).

Conclusions: The pathogen inhibition studies revealed that developed HPR-NPs were approximately four times more effective with (p < 0.05) than pure drug against sensitive Mycobacterium tuberculosis (MTB) stain. It may be concluded that HPR-NPs holds promising potential for increasing solubility and bioavailability of RMP.

Citing Articles

Recent Advances in Nanotechnology-Based Strategies for Bone Tuberculosis Management.

Luo Y, Chen H, Chen H, Xiu P, Zeng J, Song Y Pharmaceuticals (Basel). 2024; 17(2).

PMID: 38399384 PMC: 10893314. DOI: 10.3390/ph17020170.

Assessment of In Vitro Release Testing Methods for Colloidal Drug Carriers: The Lack of Standardized Protocols.

Gomez-Lazaro L, Martin-Sabroso C, Aparicio-Blanco J, Torres-Suarez A Pharmaceutics. 2024; 16(1).

PMID: 38258113 PMC: 10819705. DOI: 10.3390/pharmaceutics16010103.

Nanocarriers in Tuberculosis Treatment: Challenges and Delivery Strategies.

Kumar M, Virmani T, Kumar G, Deshmukh R, Sharma A, Duarte S Pharmaceuticals (Basel). 2023; 16(10).

PMID: 37895831 PMC: 10609727. DOI: 10.3390/ph16101360.

Synthesis, Morphology, and Rheological Evaluation of HPMA (-2-Hydroxypropyl Methacrylamide)-PCL (Polycaprolactone) Conjugates.

Rani S, Gupta U ACS Omega. 2021; 6(44):29788-29803.

PMID: 34778652 PMC: 8582054. DOI: 10.1021/acsomega.1c04243.

Recent Advances in Oral Nano-Antibiotics for Bacterial Infection Therapy.

Wu Z, Zhao J, Xu R Int J Nanomedicine. 2020; 15:9587-9610.

PMID: 33293809 PMC: 7719120. DOI: 10.2147/IJN.S279652.

References

Franzblau S, Witzig R, McLAUGHLIN J, Torres P, Madico G, Hernandez A . Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate Alamar Blue assay. J Clin Microbiol. 1998; 36(2):362-6. PMC: 104543. DOI: 10.1128/JCM.36.2.362-366.1998. View

Dvorak M, Kopeckova P, Kopecek J . High-molecular weight HPMA copolymer-adriamycin conjugates. J Control Release. 1999; 60(2-3):321-32. DOI: 10.1016/s0168-3659(99)00087-5. View

Sosnik A, Carcaboso A, Glisoni R, Moretton M, Chiappetta D . New old challenges in tuberculosis: potentially effective nanotechnologies in drug delivery. Adv Drug Deliv Rev. 2009; 62(4-5):547-59. DOI: 10.1016/j.addr.2009.11.023. View

Pandey R, Khuller G . Chemotherapeutic potential of alginate-chitosan microspheres as anti-tubercular drug carriers. J Antimicrob Chemother. 2004; 53(4):635-40. DOI: 10.1093/jac/dkh139. View

Khan I, Gothwal A, Sharma A, Qayum A, Singh S, Gupta U . Biodegradable nano-architectural PEGylated approach for the improved stability and anticancer efficacy of bendamustine. Int J Biol Macromol. 2016; 92:1242-1251. DOI: 10.1016/j.ijbiomac.2016.08.004. View

Desjardins M, Griffiths G . Phagocytosis: latex leads the way. Curr Opin Cell Biol. 2003; 15(4):498-503. DOI: 10.1016/s0955-0674(03)00083-8. View

Woo J, Cheung W, Chan R, Chan H, Cheng A, Chan K . In vitro protein binding characteristics of isoniazid, rifampicin, and pyrazinamide to whole plasma, albumin, and alpha-1-acid glycoprotein. Clin Biochem. 1996; 29(2):175-7. DOI: 10.1016/0009-9120(95)02024-1. View

Duncan R . Designing polymer conjugates as lysosomotropic nanomedicines. Biochem Soc Trans. 2007; 35(Pt 1):56-60. DOI: 10.1042/BST0350056. View

Kopecek J, Kopeckova P . HPMA copolymers: origins, early developments, present, and future. Adv Drug Deliv Rev. 2009; 62(2):122-49. PMC: 2836498. DOI: 10.1016/j.addr.2009.10.004. View

10.

Jindal K, Chaudhary R, Singla A, Gangwal S, Khanna S . Dissolution test method for rifampicin-isoniazid fixed dose formulations. J Pharm Biomed Anal. 1994; 12(4):493-7. DOI: 10.1016/0731-7085(94)80030-8. View

11.

Joshi J . Tuberculosis chemotherapy in the 21 century: Back to the basics. Lung India. 2011; 28(3):193-200. PMC: 3162758. DOI: 10.4103/0970-2113.83977. View

12.

Chan J, Zhang L, Yuet K, Liao G, Rhee J, Langer R . PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery. Biomaterials. 2008; 30(8):1627-34. DOI: 10.1016/j.biomaterials.2008.12.013. View

13.

Kopecek J, Kopeckova P, Minko T, Lu Z . HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action. Eur J Pharm Biopharm. 2000; 50(1):61-81. DOI: 10.1016/s0939-6411(00)00075-8. View

14.

Chytil P, Etrych T, Kriz J, Subr V, Ulbrich K . N-(2-Hydroxypropyl)methacrylamide-based polymer conjugates with pH-controlled activation of doxorubicin for cell-specific or passive tumour targeting. Synthesis by RAFT polymerisation and physicochemical characterisation. Eur J Pharm Sci. 2010; 41(3-4):473-82. DOI: 10.1016/j.ejps.2010.08.003. View

15.

Kalluru R, Fenaroli F, Westmoreland D, Ulanova L, Maleki A, Roos N . Poly(lactide-co-glycolide)-rifampicin nanoparticles efficiently clear Mycobacterium bovis BCG infection in macrophages and remain membrane-bound in phago-lysosomes. J Cell Sci. 2013; 126(Pt 14):3043-54. DOI: 10.1242/jcs.121814. View

16.

Nan A, Nanayakkara N, Walker L, Yardley V, Croft S, Ghandehari H . N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers for targeted delivery of 8-aminoquinoline antileishmanial drugs. J Control Release. 2001; 77(3):233-43. DOI: 10.1016/s0168-3659(01)00514-4. View

17.

PELIZZA G, Nebuloni M, Ferrari P, GALLO G . Polymorphism of rifampicin. Farmaco Sci. 1977; 32(7):471-81. View

18.

Costa P, Sousa Lobo J . Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 2001; 13(2):123-33. DOI: 10.1016/s0928-0987(01)00095-1. View

19.

Bergogne-Berezin E . Clinical role of protein binding of quinolones. Clin Pharmacokinet. 2002; 41(10):741-50. DOI: 10.2165/00003088-200241100-00004. View

20.

Rihova B, Ulbrich K, Kopecek J, Mancal P . Immunogenicity of N-(2-hydroxypropyl)-methacrylamide copolymers--potential hapten or drug carriers. Folia Microbiol (Praha). 1983; 28(3):217-27. DOI: 10.1007/BF02884085. View